PP
TCRT icon

Paloma Partners’s Alaunos Therapeutics TCRT Stock Holding History

Paloma Partners’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-116
Closed -$44K – 2202
2020
Q3 		$44K Buy
+116
New +$51.2K ﹤0.01% 1977
2019
Q4 		– Sell
-283
Closed -$182K – 2500
2019
Q3 		$182K Buy
+283
New +$225K ﹤0.01% 1770
2017
Q1 		– Sell
-85
Closed -$68K – 2230
2016
Q4 		$68K Sell
85
-182
-68% -$164K ﹤0.01% 1918
2016
Q3 		$225K Buy
267
+196
+276% +$158K ﹤0.01% 1710
2016
Q2 		$58K Buy
+71
New +$77.3K ﹤0.01% 2100
2014
Q3 		– Sell
-182
Closed -$110K – 1284
2014
Q2 		$110K Buy
+182
New +$101K ﹤0.01% 1028
2013
Q3 		– Sell
-94
Closed -$30K – 1176
2013
Q2 		$30K Buy
+94
New +$26.1K ﹤0.01% 1116

Other funds holding TCRT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Paloma Partners's TCRT Position: Q4 2020 in Review

Paloma Partners sold out of Alaunos Therapeutics (TCRT) in Q4 2020, closing a stake of 116 shares — an estimated $44K sold.

Paloma Partners first reported a position in TCRT in Q2 2013 and held it in 7 quarters. The position peaked at $225K in Q3 2016. 156 funds tracked by Wall St. Rank hold TCRT as of Q4 2020.

  • Paloma Partners reported no remaining Alaunos Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Paloma Partners sold 116 Alaunos Therapeutics shares in Q4 2020, an estimated $44K.
  • Paloma Partners first reported a position in Alaunos Therapeutics in Q2 2013 and held it in 7 quarters.
  • Paloma Partners's Alaunos Therapeutics position peaked at $225K in Q3 2016.
  • 156 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2020.

Based on Paloma Partners's 13F filing for Q4 2020, filed 16 Feb 2021.